# Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

> **NCT00483470** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 720 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Hepatitis A vaccine AVAXIM 80U
- **BIOLOGICAL:** Hepatitis A vaccine (HAVRIX 720)

## Key facts

- **NCT ID:** NCT00483470
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-05
- **Final completion:** 2008-08
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483470, "Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00483470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*